

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

PER SE TECHNOLOGIES INC

Form 10-Q

August 05, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2005

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER: 000-19480

PER-SE TECHNOLOGIES, INC.
(Exact name of Registrant as specified in its charter)

DELAWARE
(State or other jurisdiction of
incorporation or organization)

58-1651222
(I.R.S. Employer
Identification No.)

1145 SANCTUARY PARKWAY, SUITE 200
ALPHARETTA, GEORGIA
(Address of principal executive offices)

30004
(Zip code)

(770) 237-4300
(Registrant's telephone number, including area code)

NOT APPLICABLE
(Former name, former address and former fiscal year, if changed since last
report)

Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant is an accelerated filer (as

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

defined in Rule 12b-2 of the Exchange Act). Yes [X] No []

Indicate the number of shares of stock outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

TITLE OF CLASS -----	SHARES OUTSTANDING AT JULY 29, 2005 -----
Common Stock \$0.01 Par Value	32,943,419 shares
Non-voting Common Stock \$0.01 Par Value	0 Shares

PER-SE TECHNOLOGIES, INC.

FORM 10-Q
FOR THE FISCAL QUARTER ENDED JUNE 30, 2005

	PAGE -----
PART I: FINANCIAL INFORMATION	
Item 1. Financial Statements.....	2
Consolidated Balance Sheets as of June 30, 2005 and December 31, 2004 (Unaudited).....	2
Consolidated Statements of Income for the three and six months ended June 30, 2005 and 2004 (Unaudited).....	3
Consolidated Statements of Cash Flows for the six months ended June 30, 2005 and 2004 (Unaudited).....	4
Notes to Consolidated Financial Statements (Unaudited).....	5
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.....	14
Item 3. Quantitative and Qualitative Disclosures About Market Risk.....	24
Item 4. Controls and Procedures.....	24
PART II: OTHER INFORMATION	
Item 1. Legal Proceedings.....	26
Item 2c. Purchases of Equity Securities by the Issuer and Affiliated Purchasers.....	26
Item 4. Submission of Matters to a Vote of Security Holders.....	26
Item 6. Exhibits.....	27

1

PART I: FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PER-SE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

	JUNE 30, 2005	DECEMBER 31, 2004
	-----	-----
	(IN THOUSANDS, EXCEPT PAR VALUE DATA)	
CURRENT ASSETS:		
Cash and cash equivalents.....	\$ 46,166	\$ 42,422
Restricted cash.....	44	51
	-----	-----
Total cash and cash equivalents.....	46,210	42,473
Accounts receivable, billed (less allowances of \$2,951 and \$3,229 as of June 30, 2005, and December 31, 2004, respectively).....	54,584	49,105
Accounts receivable, unbilled (less allowances of \$314 and \$371 as of June 30, 2005, and December 31, 2004, respectively).....	374	302
Deferred income taxes, net.....	12,799	12,799
Prepaid expenses.....	5,114	2,823
Other.....	4,652	4,906
	-----	-----
Total current assets.....	123,733	112,408
Property and equipment, net of accumulated depreciation.....	16,309	15,512
Goodwill.....	32,549	32,549
Other intangible assets, net of accumulated amortization....	20,135	20,784
Deferred income taxes, net.....	15,316	15,316
Other.....	7,071	6,122
	-----	-----
Total assets.....	\$ 215,113	\$ 202,691
	=====	=====
CURRENT LIABILITIES:		
Accounts payable.....	\$ 5,446	\$ 5,290
Accrued compensation.....	21,005	14,562
Accrued expenses.....	12,614	14,628
Current portion of long-term debt and capital lease obligations.....	118	98
Deferred revenue.....	25,766	24,127
	-----	-----
Total current liabilities.....	64,949	58,705
Long-term debt and capital lease obligations.....	125,498	125,527
Other obligations.....	5,491	5,484
	-----	-----
Total liabilities.....	195,938	189,716
	-----	-----
STOCKHOLDERS' EQUITY:		
Preferred stock, no par value, 20,000 shares authorized; none issued.....	--	--
Common stock, voting, \$0.01 par value, 200,000 shares authorized, 32,900 and 32,324 issued and 30,912 and 30,336 outstanding as of June 30, 2005, and December 31, 2004, respectively.....	329	323
Common stock, non-voting, \$0.01 par value, 600 shares authorized; none issued.....	--	--
Paid-in capital.....	799,854	795,263
Accumulated deficit.....	(740,151)	(757,128)
Treasury stock at cost, 3,101 and 2,125 as of June 30, 2005, and December 31, 2004, respectively.....	(41,668)	(26,510)
Deferred stock unit plan obligation.....	1,280	1,511
Accumulated other comprehensive loss.....	(469)	(484)

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

Total stockholders' equity.....	19,175	12,975
Total liabilities and stockholders' equity.....	\$ 215,113	\$ 202,691

See notes to consolidated financial statements.

2

PER-SE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2005	2004	2005	2004
(IN THOUSANDS, EXCEPT PER SHARE DATA)				
Revenue.....	\$93,300	\$88,141	\$185,330	\$172,742
Operating expenses:				
Cost of services.....	62,470	56,939	122,507	112,337
Selling, general and administrative.....	21,974	22,368	43,114	43,749
Other expenses.....	--	2,538	--	6,499
Operating income.....	8,856	6,296	19,709	10,157
Interest expense.....	1,448	1,999	2,929	4,073
Interest income.....	(336)	(192)	(648)	(244)
Loss on extinguishment of debt.....	--	5,896	--	5,896
Income (loss) before income taxes.....	7,744	(1,407)	17,428	432
Income tax expense (benefit).....	198	(20)	451	212
Income (loss) from continuing operations.....	7,546	(1,387)	16,977	220
Discontinued operations (see Note 8)				
Loss from discontinued operations, net of tax -- Patient1.....	--	--	--	(18)
Gain on sale of Patient1, net of tax.....	--	3,821	--	3,755
Loss from discontinued operations, net of tax -- Business1.....	--	--	--	(303)
Loss on sale of Business1, net of tax.....	--	--	--	(130)
Loss from discontinued operations, net of tax -- Other.....	--	(30)	--	(93)
Net income.....	\$ 7,546	\$ 2,404	\$ 16,977	\$ 3,431
Net income per common share -- basic:				
Income (loss) from continuing operations.....	\$ 0.25	\$ (0.04)	\$ 0.57	\$ --
Gain on sale of Patient1, net of tax.....	--	0.12	--	0.12
Loss from discontinued operations, net of tax -- Business1.....	--	--	--	(0.01)

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

Net income per common share -- basic.....	\$ 0.25	\$ 0.08	\$ 0.57	\$ 0.11
	=====	=====	=====	=====
Weighted average shares used in computing basic earnings per share.....	29,773	31,530	30,032	31,530
	=====	=====	=====	=====
Net income per common share -- diluted:				
Income (loss) from continuing operations.....	\$ 0.23	\$ (0.04)	\$ 0.52	\$ --
Gain on sale of Patient1, net of tax.....	--	0.12	--	0.11
Loss from discontinued operations, net of tax -- Business1.....	--	--	--	(0.01)
	-----	-----	-----	-----
Net income per common share -- diluted.....	\$ 0.23	\$ 0.08	\$ 0.52	\$ 0.10
	=====	=====	=====	=====
Weighted average shares used in computing diluted earnings per share.....	32,410	31,530	32,480	33,831
	=====	=====	=====	=====

See notes to consolidated financial statements.

3

PER-SE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	SIX MONTHS ENDED JUNE 30,	
	2005	2004
	-----	-----
	(IN THOUSANDS)	
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income.....	\$ 16,977	\$ 3,431
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization.....	7,539	7,737
Loss from discontinued operations.....	--	544
Gain on sale of Patient1, net of tax.....	--	(3,755)
Amortization of deferred financing costs.....	683	665
Loss on extinguishment of debt.....	--	5,896
Changes in assets and liabilities, excluding effects of acquisitions and divestitures:		
Accounts receivable, billed.....	(5,479)	(5,150)
Accounts receivable, unbilled.....	(72)	319
Accounts payable.....	156	(2,217)
Accrued compensation.....	6,603	649
Accrued expenses.....	(2,082)	933
Deferred revenue.....	1,639	1,759
Other, net.....	(3,352)	(345)
	-----	-----
Net cash provided by continuing operations.....	22,612	10,466
Net cash used for discontinued operations.....	--	(512)
	-----	-----
Net cash provided by operating activities.....	22,612	9,954
	-----	-----
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of property and equipment.....	(4,529)	(3,000)

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

Software development costs.....	(3,373)	(2,529)
Net proceeds from sale of Patient1 and Business1, net of tax.....	--	3,625
Acquisition, net of cash acquired.....	--	(1,141)
Other.....	(163)	(35)
	-----	-----
Net cash used for investing activities.....	(8,065)	(3,080)
	-----	-----
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from borrowings.....	--	125,000
Treasury stock purchase.....	(15,404)	(24,999)
Proceeds from the exercise of stock options.....	4,600	5,258
Debt issuance costs.....	--	(5,723)
Payments of debt.....	(9)	(121,875)
Other.....	10	(108)
	-----	-----
Net cash used for financing activities.....	(10,803)	(22,447)
	-----	-----
CASH AND CASH EQUIVALENTS:		
Net change.....	3,744	(15,573)
Balance at beginning of period.....	42,422	25,271
	-----	-----
Balance at end of period.....	\$ 46,166	\$ 9,698
	=====	=====
SUPPLEMENTAL DISCLOSURES:		
Cash paid for:		
Interest.....	\$ 2,291	\$ 3,494
Income taxes.....	413	194

See notes to consolidated financial statements.

4

PER-SE TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1 -- BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements (interim financial statements) include the accounts of Per-Se Technologies, Inc. and its subsidiaries ("Per-Se" or the "Company"). Intercompany accounts and transactions have been eliminated.

These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information, the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial statements, and accounting policies consistent, in all material respects, with those applied in preparing the Company's audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2004, filed with the SEC on March 16, 2005 ("2004 Form 10-K"). These interim financial statements are unaudited but reflect all adjustments (consisting of normal recurring adjustments) management considers necessary for a fair presentation of the Company's financial position, operating results and cash flows for the interim periods presented. The information included in this report should be read in conjunction with the 2004 Form 10-K.

The consolidated financial statements of the Company have been presented to reflect the former operations of the Hospital Services division's Patient1

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

clinical product line ("Patient1") and Business1-PFM patient accounting product line ("Business1") as discontinued operations. Patient1 was sold effective July 28, 2003, and Business1 was sold effective January 31, 2004. Additionally, the activity related to the Company's former Medaphis Services Corporation and Impact Innovations Group businesses, which were sold in 1998 and 1999, respectively, are also reflected as discontinued operations for all periods presented (refer to Note 8 for additional information).

NOTE 2 -- STOCK-BASED COMPENSATION PLANS

On December 16, 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard ("SFAS") No. 123 (revised 2004), Share-Based Payment ("SFAS No. 123(R)"), which is a revision of SFAS No. 123, Accounting for Stock-Based Compensation ("SFAS No. 123"). SFAS No. 123(R) supersedes Accounting Principles Board ("APB") Opinion No. 25, Accounting for Stock Issued to Employees ("APB No. 25"), and amends SFAS No. 95, Statement of Cash Flows. SFAS No. 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. The original effective date of SFAS No. 123(R) was for interim periods beginning after June 15, 2005.

On April 14, 2005, the SEC announced the adoption of a rule that amends the compliance date for SFAS No. 123(R). SFAS No. 123(R) must be adopted by the Company no later than January 1, 2006. The Company expects to adopt SFAS No. 123(R) on January 1, 2006. When the Company adopts SFAS No. 123(R), it may elect the modified prospective method or the modified retrospective method. The Company expects to elect the modified prospective method upon adoption.

The Company currently accounts for share-based payments to employees using APB Opinion No. 25 and the intrinsic value method and, as a result, generally recognizes no compensation cost for employee stock options. Accordingly, the adoption of SFAS No. 123(R)'s fair value method will have a significant impact on the Company's results of operations, although it will have no impact on the overall cash flow or financial position of the Company. The impact of adoption of SFAS No. 123(R) cannot be determined at this time because it will depend on levels of share-based payments granted in the future. Had the Company adopted SFAS No. 123(R) in prior periods, the impact would have approximated the impact of SFAS No. 123 as described below.

5

PER-SE TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (CONTINUED)

At June 30, 2005, the Company has four stock-based compensation plans. The following table illustrates the effect on net income and net income per share if the Company had applied the fair value recognition provisions of SFAS No. 123 to its stock-based compensation plans.

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2005	2004	2005	2004
	-----	-----	-----	-----
	(IN THOUSANDS, EXCEPT PER SHARE DATA)			
Net income as reported.....	\$ 7,546	\$ 2,404	\$16,977	\$ 3,431
Deduct: total stock-based employee compensation expense determined under fair value based				

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

method for all awards, net of related tax effects.....	\$ (1,453)	\$ (1,343)	\$ (2,598)	\$ (2,225)
	-----	-----	-----	-----
Pro forma net income.....	\$ 6,093	\$ 1,061	\$14,379	\$ 1,206
	=====	=====	=====	=====
Net income per common share:				
Basic -- as reported.....	\$ 0.25	\$ 0.08	\$ 0.57	\$ 0.11
	=====	=====	=====	=====
Basic -- pro forma.....	\$ 0.20	\$ 0.03	\$ 0.48	\$ 0.04
	=====	=====	=====	=====
Diluted -- as reported.....	\$ 0.23	\$ 0.08	\$ 0.52	\$ 0.10
	=====	=====	=====	=====
Diluted -- pro forma.....	\$ 0.19	\$ 0.03	\$ 0.44	\$ 0.04
	=====	=====	=====	=====

NOTE 3 -- SHARE REPURCHASE

On March 9, 2005, the Company announced that its Board of Directors authorized the repurchase of up to one million shares of the Company's outstanding Common Stock. Under the share repurchase program, the Company was able to repurchase shares from time to time at management's discretion in the open market, by block purchase, in privately negotiated transactions or as otherwise allowed by securities laws and regulations. All shares repurchased were placed into treasury stock to be used for general corporate purposes. During the six months ended June 30, 2005, the Company repurchased one million shares of its outstanding Common Stock at a cost of approximately \$15.4 million.

NOTE 4 -- ADDITIONAL PROCEDURES

As a result of allegations of improprieties made during 2003 and 2004, the Company's external auditors advised the Company and the Audit Committee of the Board of Directors that additional procedures should be performed related to the allegations. These additional procedures were required due to Statement of Auditing Standards No. 99, Consideration of Fraud in a Financial Statement Audit, that became effective for periods beginning on or after December 15, 2002. Due to the volume and, in some cases, vague nature of many of the allegations, the scope of the additional procedures was broad and extensive. The additional procedures included the review of certain of the Company's revenues, expenses, assets and liabilities accounts for the years 2001 through 2003. Certain financial items were identified during the additional procedures that warranted the Company's further review. The Company reviewed these items and determined that it was appropriate to restate certain prior period financial statements. The restatements affected the financial statements for the years ended December 31, 2002, and 2001 and for the nine months ended September 30, 2003. The net result of these restatements was a total increase in net income of approximately \$2.1 million for the years 2001 and 2002, and for the nine months ended September 30, 2003.

The Company recorded costs related to the additional procedures totaling approximately \$2.5 and \$6.5 million during the three and six months ended June 30, 2004, respectively, and included these costs in other

expenses in the Company's Consolidated Statements of Income. In Note 13, these expenses are classified in the Corporate segment.

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

NOTE 5 -- ACQUISITIONS

On May 28, 2004, the Company entered into a five-year contract to provide print and mail services for a new customer. As part of the transaction, the Company purchased substantially all of the production assets and personnel of that customer's hospital and physician patient statement and paper claims print and mail business for cash consideration of approximately \$1.1 million. In addition, the Company recorded acquisition liabilities of approximately \$1.0 million associated with the transaction.

The Company recorded the acquisition using the purchase method of accounting and, accordingly, has allocated the purchase price to the assets acquired and liabilities assumed based on their estimated fair market value at the date of acquisition. Approximately \$1.9 million of the purchase price was allocated to a finite-lived intangible asset with a five-year life. The remaining \$0.2 million of the purchase price was allocated to tangible assets acquired. The operating results of the acquisition are included in the Company's Consolidated Statements of Income from the date of acquisition in the Hospital Services division.

The pro-forma impact of this acquisition was immaterial to the financial statements of the Company and therefore has not been presented.

NOTE 6 -- EARNINGS PER SHARE

Basic earnings per share ("EPS") is calculated by dividing net income by the weighted average number of shares of Common Stock outstanding during the period. Diluted EPS reflects the potential dilution that could occur from common shares issuable through stock options. The following sets forth the computation of basic and diluted net income per share for the three and six months ended June 30, 2005, and 2004:

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2005	2004	2005	2004
	(IN THOUSANDS, EXCEPT PER SHARE DATA)			
Net income.....	\$7,546	\$2,404	\$16,977	\$3,431
	=====	=====	=====	=====
Common shares outstanding:				
Shares used in computing net income per common				
share -- basic.....	29,773	31,530	30,032	31,530
Effect of potentially dilutive stock options and				
warrants.....	2,637	--	2,448	2,301
	-----	-----	-----	-----
Shares used in computing net income per common				
share -- diluted.....	32,410	31,530	32,480	33,831
	=====	=====	=====	=====
Net income per common share:				
Basic.....	\$ 0.25	\$ 0.08	\$ 0.57	\$ 0.11
	=====	=====	=====	=====
Diluted.....	\$ 0.23	\$ 0.08	\$ 0.52	\$ 0.10
	=====	=====	=====	=====

Options to purchase 0.2 million and 0.6 million shares of Common Stock outstanding during the three and six months ended June 30, 2005, respectively, were excluded from the computation of diluted earnings per share because the

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

exercise prices of the options were greater than the average market price of the common shares, and therefore, the effect would have been antidilutive.

During the three months ended June 30, 2005, the Company's average market price exceeded the market trigger price of the Company's contingently convertible debt instrument and as such, the computation of diluted

7

PER-SE TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (CONTINUED)

earnings per share includes approximately 14,000 shares related to the convertible debt instrument (see Note 10 for additional information).

Options and warrants to purchase 7.0 million shares of Common Stock outstanding during the three months ended June 30, 2004, were excluded from the computation of diluted earnings per share due to their antidilutive effect as a result of the Company's loss from continuing operations for the period.

Options and warrants to purchase 1.7 million shares of Common Stock outstanding during the six months ended June 30, 2004, were excluded from the computation of diluted earnings per share because the exercise prices of the options and warrants were greater than the average market price of the common shares, and therefore, the effect would have been antidilutive.

NOTE 7 -- FOREIGN CURRENCY TRANSLATION AND COMPREHENSIVE INCOME

The functional currency of the Company's operations outside of the United States is the local country's currency. Consequently, assets and liabilities of operations outside the United States are translated into dollars using exchange rates at the end of each reporting period. Revenue and expenses are translated at the average exchange rates prevailing during the period. Cumulative translation gains and losses are reported in accumulated other comprehensive loss. In the three-month periods ended June 30, 2005, and 2004, the only component of other comprehensive loss was the net foreign currency translation.

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2005	2004	2005	2004
	-----	-----	-----	-----
	(IN THOUSANDS)			
Net foreign currency translation.....	\$ (21)	\$13	\$ (15)	\$ (15)

NOTE 8 -- DISCONTINUED OPERATIONS AND DIVESTITURES

The Company completed the sale of Patient1 to Misys Healthcare Systems, a division of Misys plc on July 28, 2003. The Company completed the sale of Business1 effective January 31, 2004, to a privately held company for \$0.6 million, which will be received in periodic payments through June 2006. No cash consideration was received at closing.

Pursuant to SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, the consolidated financial statements of the Company have been presented to reflect Patient1 and Business1 as discontinued operations for

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

all periods presented. Patient1 and Business1 were formerly reported as part of the Hospital Services division.

Summarized operating results for the discontinued operations are as follows:

	SIX MONTHS ENDED JUNE 30, 2004		
	PATIENT1	BUSINESS1	TOTAL
	(IN THOUSANDS)		
Revenue.....	\$ --	\$ 106	\$ 106
	=====	=====	=====
Loss from discontinued operations before income taxes.....	\$ (18)	\$ (303)	\$ (321)
Income tax expense.....	--	--	--
	-----	-----	-----
Loss from discontinued operations, net of tax.....	\$ (18)	\$ (303)	\$ (321)
	=====	=====	=====

8

PER-SE TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (CONTINUED)

NOTE 9 -- LEGAL MATTERS

On April 4, 2005, the Company announced that it was notified by the SEC of the issuance of an order of investigation, which it believes relates to allegations of wrongdoing made by a former employee in 2003 and 2004. These allegations were the subject of a prior investigation by the audit committee and an outside accounting firm that resulted in the performance of extensive additional procedures. See Note 4 above and "Note 2 -- "Other Expenses" in the Company's Notes to the Consolidated Financial Statements in the Company's 2004 Form 10-K for more information.

The Company is subject to claims, litigation and official billing inquiries arising in the ordinary course of its business. These matters include, but are not limited to, lawsuits brought by former customers with respect to the operation of the Company's business. The Company has also received written demands from customers and former customers that have not resulted in legal action. Within the Company's industry, federal and state civil and criminal laws govern medical billing and collection activities. These laws provide for various fines, penalties, multiple damages, assessments and sanctions for violations, including possible exclusion from federal and state healthcare payer programs.

The Company believes that it has meritorious defenses to the claims and other issues asserted in pending legal matters; however, there can be no assurance that such matters or any future legal matters will not have an adverse effect on the Company. Amounts of awards or losses, if any, in pending legal matters have not been reflected in the financial statements unless probable and reasonably estimable.

NOTE 10 -- LONG-TERM DEBT

On June 30, 2004, the Company issued \$125 million aggregate principal amount of 3.25% Convertible Subordinated Debentures due 2024 (the "Debentures")

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

to qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended. As originally issued, the Debentures were convertible into shares of the Company's Common Stock at an initial conversion rate of 56.0243 shares per \$1,000 principal amount (a conversion price of approximately \$17.85) once the Company's Common Stock share price reaches 130% of the conversion price, or a share price of approximately \$23.20. In November 2004, the Company exercised its irrevocable option to pay the principal of Debentures submitted for conversion in cash. The Company will satisfy any amount above the conversion trigger price of \$17.85 through the issuance of Common Stock. The Debentures mature on June 30, 2024, and are unsecured. Interest on the Debentures is payable semiannually at the rate of 3.25% per annum on June 30 and December 30 of each year, beginning on December 30, 2004. The Company may redeem the Debentures either in whole or in part beginning July 6, 2009. The holders may require the Company to repurchase the Debentures on June 30, 2009, 2014, and 2019, or upon a fundamental change, as defined in the Indenture governing the Debentures. The Company used the proceeds from issuance of the Debentures, together with cash on hand, to retire its then-outstanding \$118.8 million of debt, as well as to repurchase, for approximately \$25 million, an aggregate of approximately 2.0 million shares of the Company's outstanding common stock, at the market price of \$12.57 per share, in negotiated transactions concurrently with the Debentures offering.

In connection with the sale of the Debentures, the Company agreed to file with the SEC, within 90 days after the original issuance of the Debentures, a shelf registration statement with respect to the resale of the Debentures and the common stock issuable upon conversion of the Debentures. The Company agreed to use commercially reasonable efforts to cause the shelf registration statement to become effective within 210 days after the original issuance of the Debentures. On September 15, 2004, the Company filed the shelf registration statement with the SEC. On March 14, 2005, the shelf registration became effective. Since the Company was unable to cause the shelf registration statement to become effective within 210 days after original issuance of the Debentures, the Company was required to pay an additional 0.25% of interest on the Debentures from January 26, 2005, through the effective date of the shelf registration statement, March 14, 2005. The Company paid approximately \$41,000 of additional interest to holders of the Debentures for the period from January 26, 2005, through March 14, 2005.

9

PER-SE TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (CONTINUED)

On June 30, 2004, the Company also amended its then-current credit facility to increase its capacity from \$50 million to \$75 million, to extend its maturity to three years, and to lower the interest rate from LIBOR plus amounts ranging from 3.0% to 3.5% to LIBOR plus amounts ranging from 2.5% to 3.0% ("Revolving Credit Facility"). The Company intends to use the Revolving Credit Facility, as needed, for future investments in operations, including capital expenditures, strategic acquisitions, to secure its letters of credit, as needed, and other general corporate purposes. The Company has not incurred any borrowings under the Revolving Credit Facility as of June 30, 2005.

All obligations under the Revolving Credit Facility are fully and unconditionally guaranteed, on a senior secured basis, jointly and severally by all of the Company's present and future domestic and material foreign subsidiaries (the "Subsidiary Guarantors"). The financial statements of the Subsidiary Guarantors have not been presented, as all subsidiaries, except for certain minor foreign subsidiaries, have provided guarantees, and the parent company does not have any significant operations or assets separate from its investment in those subsidiaries. Any non-guarantor subsidiaries are minor

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

individually and in the aggregate to the Company's consolidated financial statements. There are no restrictions on the Subsidiary Guarantors that would prohibit the transfer of funds or assets to the parent company by dividend or loan.

The Revolving Credit Facility contains financial and other restrictive covenants, including, without limitation, those restricting additional indebtedness, lien creation, dividend payments, asset sales and stock offerings, and those requiring a minimum net worth, maximum leverage and minimum fixed charge coverage, each as defined in the Revolving Credit Facility. The Company was in compliance with all applicable covenants as of June 30, 2005.

NOTE 11 -- INCOME TAXES

Income tax expense, which was primarily related to federal, state and local income taxes, was approximately \$0.2 million and \$0.5 million for the three and six months ended June 30, 2005, respectively, as compared to an income tax benefit of approximately \$20,000 for the three months ended June 30, 2004, and an income tax expense of approximately \$0.2 million for the six months ended June 30, 2004. The Company has historically had a full valuation allowance against its deferred tax asset due to the uncertainty regarding its ability to generate sufficient future taxable income prior to the expiration of its net operating loss carryforwards. In the fourth quarter of 2004, the Company reassessed the valuation allowance previously established and determined that it was more likely than not that a portion of the deferred tax asset would be realized in the foreseeable future. This determination was based upon the Company's projection of taxable income for 2005 and 2006. Accordingly, a portion of the valuation allowance was released during the fourth quarter of 2004. The Company will continue to assess the potential realization of the remaining deferred tax asset, and will adjust the valuation allowance in future periods, as appropriate. During the current period, the Company utilized net operating losses to offset current period taxable income which significantly reduced the Company's effective tax rate.

NOTE 12 -- RESTRUCTURING EXPENSES

The amount of lease termination costs associated with a 1995 restructuring applied against the reserve in the six months ended June 30, 2005, is as follows:

	RESERVE BALANCE DECEMBER 31, 2004 -----	COSTS APPLIED AGAINST RESERVE ----- (IN THOUSANDS)	RESERVE BALANCE JUNE 30, 2005 -----
Lease termination costs.....	\$1,104	\$(168)	\$936

NOTE 13 -- SEGMENT REPORTING

The Company's reportable segments are operating units that offer different services and products. Per-Se provides its services and products through its two operating divisions: Physician Services and Hospital Services.

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

The Physician Services division provides Connective Healthcare solutions that manage the revenue cycle for physician groups. The division is the largest provider of business management outsourced services that supplant all or most of the administrative functions of a physician group related to their revenue cycle. The target market is primarily hospital-affiliated physician groups in the specialties of radiology, anesthesiology, emergency medicine and pathology as well as physician groups practicing in the academic setting and other large physician groups. The division recognizes revenue primarily on a contingency fee basis, which aligns the division's interests with the interests of the physician groups it services. The outsourced services business recognizes revenue as a percentage of the physician group's cash collections for the services performed. Since this is an outsourced service delivered on the Company's proprietary technology, license fees or maintenance fees are not required to be paid by the division's hospital-affiliated physician groups. The division also sells a physician practice management ("PPM") solution that is delivered via an ASP model. The PPM solution collects a monthly usage fee from the office-based physician practices using the system. The division's revenue model is 100% recurring in nature due to the transaction-based nature of its fee revenue in the outsourced services business and the monthly usage fee in the PPM business. The business of the Physician Services division is conducted by PST Services, Inc. a Georgia corporation d/b/a "Per-Se Technologies," which is a wholly owned subsidiary of the Company.

The Hospital Services division provides Connective Healthcare solutions that increase revenue and decrease expenses for hospitals, with a focus on revenue cycle management and resource management. The division's revenue cycle management solutions enable a hospital's central billing office to improve its revenue cycle. The division has one of the largest clearinghouses in the medical industry, which provides an important infrastructure to support its revenue cycle offering. The division also provides resource management solutions that enable hospitals efficiently to manage resources, such as personnel and the operating room, to reduce costs and improve their bottom line. The division primarily recognizes revenue on a per-transaction basis for its revenue cycle management solutions and primarily recognizes revenue on a percentage-of-completion basis or upon software shipment for sales of its resource management software solutions. Approximately 88% of the division's revenue is recurring due to its transaction-based business and the maintenance revenue from its substantial installed base for the resource management software solutions. The business of the Hospital Services division is conducted by the following wholly owned subsidiaries of the Company: Per-Se Transaction Services, Inc., an Ohio corporation; Patient Account Management Services, Inc., an Ohio corporation; PST Products, LLC, a California limited liability company; and Knowledgeable Healthcare Solutions, Inc., an Alabama corporation. All of these subsidiaries do business under the name "Per-Se Technologies."

The Company evaluates each segment's performance based on its segment operating income. Segment operating income is revenue less cost of services, selling, general and administrative expenses and other expenses.

The Hospital Services segment revenue includes intersegment revenue for services provided to the Physician Services segment, which are shown as eliminations to reconcile to total consolidated revenue.

11

PER-SE TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (CONTINUED)

The Company's segment information from continuing operations is as follows:

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2005	2004	2005	2004
	(IN THOUSANDS)		(IN THOUSANDS)	
Revenue:				
Physician Services.....	\$69,068	\$66,075	\$136,258	\$129,258
Hospital Services.....	27,808	25,446	56,172	50,217
Eliminations.....	(3,576)	(3,380)	(7,100)	(6,733)
	=====	=====	=====	=====
	\$93,300	\$88,141	\$185,330	\$172,742
	=====	=====	=====	=====
Segment operating expenses:				
Physician Services.....	\$61,581	\$58,958	\$120,203	\$116,188
Hospital Services.....	22,547	19,078	44,482	38,047
Corporate.....	3,892	7,189	8,036	15,083
Eliminations.....	(3,576)	(3,380)	(7,100)	(6,733)
	=====	=====	=====	=====
	\$84,444	\$81,845	\$165,621	\$162,585
	=====	=====	=====	=====
Segment operating income:				
Physician Services.....	\$ 7,487	\$ 7,117	\$ 16,055	\$ 13,070
Hospital Services.....	5,261	6,368	11,690	12,170
Corporate.....	(3,892)	(7,189)	(8,036)	(15,083)
	=====	=====	=====	=====
	\$ 8,856	\$ 6,296	\$ 19,709	\$ 10,157
	=====	=====	=====	=====
Interest expense.....	\$ 1,448	\$ 1,999	\$ 2,929	\$ 4,073
	=====	=====	=====	=====
Interest income.....	\$ (336)	\$ (192)	\$ (648)	\$ (244)
	=====	=====	=====	=====
Loss on extinguishment of debt.....	\$ --	\$ 5,896	\$ --	\$ 5,896
	=====	=====	=====	=====
Income (loss) before income taxes.....	\$ 7,744	\$ (1,407)	\$ 17,428	\$ 432
	=====	=====	=====	=====
Depreciation and amortization:				
Physician Services.....	\$ 2,097	\$ 2,341	\$ 4,157	\$ 4,765
Hospital Services.....	1,615	1,380	3,211	2,700
Corporate.....	75	122	171	272
	=====	=====	=====	=====
	\$ 3,787	\$ 3,843	\$ 7,539	\$ 7,737
	=====	=====	=====	=====
Capital expenditures and capitalized software development costs:				
Physician Services.....	\$ 1,511	\$ 1,080	\$ 3,489	\$ 2,690
Hospital Services.....	1,457	1,387	4,050	2,537
Corporate.....	309	298	363	302
	=====	=====	=====	=====
	\$ 3,277	\$ 2,765	\$ 7,902	\$ 5,529
	=====	=====	=====	=====

AS OF

-----	-----
JUNE 30,	DECEMBER 31,
2005	2004
-----	-----

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

(IN THOUSANDS)

Identifiable assets:		
Physician Services.....	\$ 68,170	\$ 63,611
Hospital Services.....	64,107	59,964
Corporate.....	82,836	79,116
	-----	-----
	\$215,113	\$202,691
	=====	=====

12

PER-SE TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (CONTINUED)

NOTE 14 -- ENHANCEMENT TO PHYSICIAN CLAIMS CLEARINGHOUSE PROJECT

During the latter part of 2004, the Company initiated a project to enhance substantially its physician claims clearinghouse functionality. The Company expects that the improved platform will provide efficiencies and competitive advantages for its Physician Services division. The Company expects to incur approximately \$3 million in capital expenditures and capitalized software development costs and approximately \$1.5 million in expenses related to the physician claims clearinghouse enhancement in 2005. During the six months ended June 30, 2005, the Company incurred approximately \$0.7 million of expenses which are reflected in the Hospital Services division, and invested approximately \$1.3 million for capital expenditures and capitalized software development costs related to this project. The Company expects the project to be completed in mid-2006.

13

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

DESCRIPTION OF BUSINESS

Per-Se Technologies, Inc. ("Per-Se" or the "Company"), a corporation organized in 1985 under the laws of the State of Delaware, provides integrated business management outsourcing services, Internet-enabled connectivity and administrative software for the healthcare industry. Per-Se delivers its services and products through its two operating divisions: Physician Services and Hospital Services.

The Physician Services division provides business management outsourcing services to the hospital-affiliated physician practice market, physicians in academic settings and other large physician practices. The division provides a complete outsourcing service, therefore, allowing physician groups to avoid the infrastructure investment in their own in-house billing office. Services include clinical data collection, data input, medical coding, billing, contract management, cash collections and accounts receivable management. These services are designed to assist healthcare providers with the business management functions associated with the delivery of healthcare services, allowing physicians to focus on providing quality patient care. These services also assist physicians in improving cash flows and reducing administrative costs and burdens. The division's offerings have historically focused on the back-end processes required to ensure physicians are properly reimbursed for care delivery. The division also has an ASP-based physician practice management solution, named MedAxxis, that targets office-based physician groups.

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

The Hospital Services division products focus on optimizing the revenue cycle and improving administrative efficiencies for hospitals. Solutions include electronic claims processing, referral submissions, eligibility verification and other electronic and paper transaction processing as well as patient and staff scheduling systems.

Per-Se markets its products and services to constituents of the healthcare industry, primarily to hospital-affiliated physician practices, physician groups in academic settings, hospitals and integrated delivery networks ("IDNs").

GENERAL OVERVIEW

Management believes the key elements for assessing the Company's performance are the ability to generate stable and improving operating profit margins on the Company's existing business, and to generate similar or better operating profit margins on new business. An additional element is the ability to generate positive cash flow from continuing operations. In assessing the Company's performance, adjustments are made for items the Company considers to be atypical, such as those noted below, to help ensure the analysis is performed on a consistent, comparable basis from period to period.

Consolidated revenue for the three months ended June 30, 2005, increased approximately 6% as compared to the same period of 2004 due to the implementation of the record level of new business sold during 2004. Consolidated operating margins increased from 7.1% in the second quarter of 2004 to 9.5% in the second quarter of 2005. During the second quarter of 2004, the Company incurred approximately \$2.5 million in costs associated with the additional procedures as part of the year-end 2003 audit. Similar costs were not incurred during the second quarter of 2005. Operating margins also increased due to the increased revenue in the Physician Services division.

The Company generated approximately \$22.6 million in cash from continuing operations during the six months ended June 30, 2005 as compared to \$10.5 million during the same period of 2004. The increase in cash flow from continuing operations was driven by the Company's increase in profitability and the timing of payments on certain liabilities.

During the latter part of 2004, the Company initiated a project to enhance substantially its physician claims clearinghouse functionality. The Company expects that the improved platform will provide efficiencies and competitive advantages for its Physician Services division. The Company expects to incur approximately \$3 million in capital expenditures and capitalized software development costs and approximately \$1.5 million in expenses related to the physician claims clearinghouse enhancement. During the six months ended June 30, 2005, the Company incurred approximately \$0.7 million of expenses which are reflected in the Hospital Services

14

division, and invested approximately \$1.3 million for capital expenditures and capitalized software development costs related to this project. The Company expects the project to be completed in mid-2006.

RESULTS OF OPERATIONS

THREE MONTHS ENDED JUNE 30, 2005, AS COMPARED TO THREE MONTHS ENDED JUNE 30, 2004

Revenue. Revenue classified by the Company's reportable segments ("divisions") is as follows:

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

	THREE MONTHS ENDED JUNE 30,	
	2005	2004
	(IN THOUSANDS)	
Physician Services.....	\$69,068	\$66,075
Hospital Services.....	27,808	25,446
Eliminations.....	(3,576)	(3,380)
	-----	-----
	\$93,300	\$88,141
	=====	=====

Revenue for the Physician Services division increased approximately 5% in the three months ended June 30, 2005, as compared to the same period in 2004. Pricing for the division's services and products was stable compared to the prior year period. The revenue increase is due to the implementation of the record level of new business sold during 2004. Net new business sold during the second quarter of 2005 was \$10 million compared to \$2 million during the second quarter of 2004. Current year net new business sold represents the Company's strongest second quarter performance. Net new business sold is defined as the annualized revenue value of new contracts signed in a period, less the annualized revenue value of terminated business in that same period. Net backlog at June 30, 2005, was approximately \$10 million, compared to the net backlog of approximately \$5 million at March 31, 2005. Net backlog represents the annualized revenue related to new contracts signed with the business still to be implemented, less the annualized revenue related to existing contracts where discontinuance notification has been received and the customer has yet to be phased out. The Company focuses on maintaining a positive net backlog and believes it is a useful indicator of future revenue growth.

Revenue for the Hospital Services division increased approximately 9% for the three months ended June 30, 2005, as compared to the same period in 2004. Pricing for the division's services and products was stable compared to the prior year period. Revenue growth in the division is due to the implementation of transaction processing new business sold during 2004. Medical transaction volume increased approximately 16% for the period over the same period of 2004. Revenue growth does not necessarily correlate directly to transaction volume due to the mix of services and products sold by the division. The Company believes transaction volume is a useful indicator of future revenue growth as business is implemented into the division's recurring revenue model.

The Hospital Services division revenue includes intersegment revenue for services provided to the Physician Services division, which is shown in Eliminations to reconcile to total consolidated revenue.

Segment Operating Income. Segment operating income is revenue less cost of services, selling, general and administrative expenses and other expenses. Segment operating income, classified by the Company's divisions, is as follows:

	THREE MONTHS ENDED JUNE 30,	
	2005	2004
	-----	-----

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

(IN THOUSANDS)

Physician Services.....	\$ 7,487	\$ 7,117
Hospital Services.....	5,261	6,368
Corporate.....	(3,892)	(7,189)
	-----	-----
	\$ 8,856	\$ 6,296
	=====	=====

15

Physician Services' segment operating income increased approximately 5% in the three months ended June 30, 2005, compared to the same period in 2004, resulting in operating margins of approximately 10.8% in both periods. Margins in the current year period were negatively impacted by results for the division's physician practice management ("PPM") solution, which represents less than 5% of the division's total revenue. The Company is in the final stages of converting its PPM customers to a new platform. During the conversion, which is expected to be completed by the end of 2005, the Company is incurring costs to support both the legacy platform and the new platform, resulting in lower than normal margins for this business.

Hospital Services' segment operating income decreased approximately 17% in the three months ended June 30, 2005, compared to the same period in 2004, resulting in operating margins of approximately 18.9% versus approximately 25.0% in the prior year period. Included in the current year quarter is approximately \$0.4 million of costs associated with the Company's physician claims clearinghouse enhancement. Also, operating margins in the prior year period were higher due to the previously unbilled maintenance revenue that was being recognized upon receipt of payment.

Corporate overhead expenses, which include certain executive and administrative functions, decreased approximately \$3.3 million or approximately 46% in the three months ended June 30, 2005, compared to the same period in 2004. The decrease is attributable primarily to approximately \$2.5 million of expenses incurred in the three months ended June 30, 2004, to perform the additional procedures discussed below.

Other Expenses. As a result of allegations of improprieties made during 2003 and 2004, the Company's external auditors advised the Company and the Audit Committee of the Board of Directors that additional procedures should be performed related to the allegations. These additional procedures were required due to Statement of Auditing Standards ("SAS") No. 99, Consideration of Fraud in a Financial Statement Audit ("SAS No. 99"), that became effective for periods beginning on or after December 15, 2002. Due to the volume and, in some cases, vague nature of many of the allegations, the scope of the additional procedures was broad and extensive. The additional procedures included the review of certain of the Company's revenues, expenses, assets and liabilities accounts for the years 2001 through 2003.

The Company recorded costs related to the additional procedures totaling approximately \$2.5 million during the three months ended June 30, 2004, and included these costs in other expenses in the Company's Consolidated Statements of Income. In Note 13 of Notes to Financial Statements, these expenses are classified in the Corporate segment.

Interest. Interest expense was approximately \$1.4 million for the three months ended June 30, 2005, as compared to \$2.0 million for the same period in 2004. The decrease is attributable to the Company refinancing its debt in June 2004, by issuing \$125 million aggregate principal amount of 3.25% Convertible

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

Subordinated Debentures due 2024. Prior to this refinancing, the interest rate on the Term Loan B was LIBOR plus 4.25%, or approximately 5.36%, in the second quarter of 2004. Interest income was approximately \$0.3 million for the three-month period ended June 30, 2005, as compared to approximately \$0.2 million for the same period in 2004.

Loss on Extinguishment of Debt. During the three months ended June 30, 2004, in connection with the retirement of the Company's then-outstanding \$118.8 million under the Term Loan B component of the Credit Agreement (the "Term Loan B"), the Company wrote off approximately \$3.5 million of deferred debt issuance costs associated with the Term Loan B. Additionally, the Company incurred a prepayment penalty of approximately \$2.4 million due to the early retirement of the Term Loan B.

Income Taxes. Income tax expense, which was primarily related to federal, state and local income taxes, was approximately \$0.2 million and (\$20,000) for the three months ended June 30, 2005, and 2004, respectively. The Company has historically had a full valuation allowance against its deferred tax asset due to the uncertainty regarding its ability to generate sufficient future taxable income prior to the expiration of its net operating loss carryforwards. In the fourth quarter of 2004, the Company reassessed the valuation allowance previously established and determined that it was more likely than not that a portion of the deferred tax asset would be realized in the foreseeable future. This determination was based upon the Company's projection of taxable income for 2005 and 2006. Accordingly, a portion of the valuation allowance was released during the fourth quarter of 2004. The Company will continue to assess the potential realization of the remaining deferred tax

16

asset, and will adjust the valuation allowance in future periods, as appropriate. During the current period, the Company utilized net operating losses to offset current period taxable income which significantly reduced the Company's effective tax rate.

Discontinued Operations. The Company completed the sale of Patient1 to Misys Healthcare Systems, a division of Misys plc ("Misys") on July 28, 2003. The Company completed the sale of Business1 effective January 31, 2004, to a privately held company for \$0.6 million, which will be received in periodic payments through June 2006. No cash consideration was received at closing.

Pursuant to SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, the consolidated financial statements of the Company have been presented to reflect Patient1 and Business1 as discontinued operations for all periods presented. Patient1 and Business1 were formerly reported as part of the Hospital Services division.

SIX MONTHS ENDED JUNE 30, 2005, AS COMPARED TO THREE MONTHS ENDED JUNE 30, 2004

Revenue. Revenue classified by the Company's reportable segments ("divisions") is as follows:

SIX MONTHS ENDED JUNE 30,	
2005	2004
(IN THOUSANDS)	

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

Physician Services.....	\$136,258	\$129,258
Hospital Services.....	56,172	50,217
Eliminations.....	(7,100)	(6,733)
	-----	-----
	\$185,330	\$172,742
	=====	=====

Revenue for the Physician Services division increased approximately 5% in the six months ended June 30, 2005, as compared to the same period in 2004. Pricing for the division's services and products was stable compared to the prior year period. The revenue increase is due to the implementation of the record net new business sold during 2004 and the recognition of approximately \$1.5 million of revenue delayed in the quarter ended December 31, 2004, caused by a technical problem in the claims clearinghouse. Net new business sold during the second quarter of 2005 was \$10 million compared to \$2 million during the second quarter of 2004. The current year quarter represents the second highest net new business sold performance for the division. Net new business sold is defined as the annualized revenue value of new contracts signed in a period, less the annualized revenue value of terminated business in that same period. Net backlog at June 30, 2005, was approximately \$10 million, compared to the net backlog of approximately \$3 million at June 30, 2004. Net backlog represents the annualized revenue related to new contracts signed with the business still to be implemented, less the annualized revenue related to existing contracts where discontinuance notification has been received and the customer has yet to be phased out. The Company focuses on maintaining a positive net backlog and believes it is a useful indicator of future revenue growth.

Revenue for the Hospital Services division increased approximately 12% for the six months ended June 30, 2005, as compared to the same period in 2004. Pricing for the division's services and products was stable compared to the prior year period. Revenue growth in the division is due to the implementation of new transaction processing business sold during 2004. Medical transaction volume increased approximately 20% for the period over the same period of 2004. Revenue growth does not necessarily correlate directly to transaction volume due to the mix of services and products sold by the division. The Company believes transaction volume is a useful indicator of future revenue growth as business is implemented into the division's recurring revenue model.

The Hospital Services division revenue includes intersegment revenue for services provided to the Physician Services division, which is shown in Eliminations to reconcile to total consolidated revenue.

17

Segment Operating Income. Segment operating income is revenue less cost of services, selling, general and administrative expenses and other expenses. Segment operating income, classified by the Company's divisions, is as follows:

	SIX MONTHS ENDED JUNE 30,	
	2005	2004
	-----	-----
	(IN THOUSANDS)	
Physician Services.....	\$16,055	\$ 13,070
Hospital Services.....	11,690	12,170

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

Corporate.....	(8,036)	(15,083)
	-----	-----
	\$19,709	\$ 10,157
	=====	=====

Physician Services' segment operating income increased approximately 23% in the six months ended June 30, 2005, compared to the same period in 2004, resulting in operating margins of approximately 11.8% in the six months ended June 30, 2005, versus approximately 10.1% in the same period in 2004. Margin expansion in the current year period is the result of revenue growth as well as the recognition of approximately \$1.5 million of revenue delayed in the quarter ended December 31, 2004, caused by a technical problem in the claims clearinghouse. Margins in the current year were negatively impacted by results for the division's PPM solution, which represents less than 5% of the division's total revenue. The Company is in the final stages of converting its PPM customers to a new platform. During the conversion, which is expected to be completed by the end of 2005, the Company is incurring costs to support both the legacy platform and the new platform, resulting in lower than normal margins for this business.

Hospital Services' segment operating income decreased approximately 4% in the six months ended June 30, 2005, compared to the same period in 2004, resulting in operating margins of approximately 20.8% versus approximately 24.2% in the prior year period. The current year includes approximately \$0.7 million of costs associated with the Company's physician claims clearinghouse enhancement. Also, operating margins in the prior year period were higher due to the previously unbilled maintenance revenue that was being recognized upon receipt of payment.

Corporate overhead expenses, which include certain executive and administrative functions, decreased approximately \$7.0 million or approximately 47% in the six months ended June 30, 2005, compared to the same period in 2004. The decrease is attributable primarily to approximately \$6.5 million of expenses incurred in the six months ended June 30, 2004, to perform the additional procedures discussed below.

Other Expenses. As a result of allegations of improprieties made during 2003 and 2004, the Company's external auditors advised the Company and the Audit Committee of the Board of Directors that additional procedures should be performed related to the allegations. These additional procedures were required due to SAS No. 99, that became effective for periods beginning on or after December 15, 2002. Due to the volume and, in some cases, vague nature of many of the allegations, the scope of the additional procedures was broad and extensive. The additional procedures included the review of certain of the Company's revenues, expenses, assets and liabilities accounts for the years 2001 through 2003.

The Company recorded costs related to the additional procedures totaling approximately \$6.5 million during the six months ended June 30, 2004, and included these costs in other expenses in the Company's Consolidated Statements of Income. In Note 13 of Notes to Financial Statements, these expenses are classified in the Corporate segment.

Interest. Interest expense was approximately \$2.9 million for the six months ended June 30, 2005, as compared to \$4.1 million for the same period in 2004. The decrease is attributable to the Company refinancing its debt in June 2004, by issuing \$125 million aggregate principal amount of 3.25% Convertible Subordinated Debentures due 2024. Prior to this refinancing, the interest rate on the Term Loan B was LIBOR plus 4.25%, or approximately 5.39%, in the first six months of 2004. Interest income was approximately \$0.6 million for the six-month period ended June 30, 2005, as compared to approximately \$0.2 million for

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

the same period in 2004.

18

Income Taxes. Income tax expense, which was primarily related to federal, state and local income taxes, was approximately \$0.5 million and \$0.2 million for the six months ended June 30, 2005, and 2004, respectively. The Company has historically had a full valuation allowance against its deferred tax asset due to the uncertainty regarding its ability to generate sufficient future taxable income prior to the expiration of its net operating loss carryforwards. In the fourth quarter of 2004, the Company reassessed the valuation allowance previously established and determined that it was more likely than not that a portion of the deferred tax asset would be realized in the foreseeable future. This determination was based upon the Company's projection of taxable income for 2005 and 2006. Accordingly, a portion of the valuation allowance was released during the fourth quarter of 2004. The Company will continue to assess the potential realization of the remaining deferred tax asset, and will adjust the valuation allowance in future periods, as appropriate. During the current period, the Company utilized net operating losses to offset current period taxable income which significantly reduced the Company's effective tax rate.

Discontinued Operations. The Company completed the sale of Patient1 to Misys on July 28, 2003. The Company completed the sale of Business1 effective January 31, 2004, to a privately held company for \$0.6 million, which will be received in periodic payments through June 2006. No cash consideration was received at closing.

Pursuant to SFAS No. 144, the consolidated financial statements of the Company have been presented to reflect Patient1 and Business1 as discontinued operations for all periods presented. Patient1 and Business1 were formerly reported as part of the Hospital Services division.

Summarized operating results for the discontinued operations are as follows:

	SIX MONTHS ENDED JUNE 30, 2004		
	PATIENT1	BUSINESS1	TOTAL
	(IN THOUSANDS)		
Revenue.....	\$ --	\$ 106	\$ 106
	====	=====	=====
Loss from discontinued operations before income taxes.....	\$ (18)	\$ (303)	\$ (321)
Income tax expense.....	--	--	--
	----	-----	-----
Loss from discontinued operations, net of tax.....	\$ (18)	\$ (303)	\$ (321)
	====	=====	=====

LIQUIDITY AND CAPITAL RESOURCES

The following table is a summary of the Company's cash balances as of June 30, 2005, and December 31, 2004, and cash flows from continuing operations for the six months ended June 30, 2005, and 2004, (in thousands):

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

	JUNE 30, 2005	DECEMBER 31, 2004
	-----	-----
Unrestricted cash and cash equivalents.....	\$46,166	\$42,422
	SIX MONTHS ENDED JUNE 30,	
	-----	-----
	2005	2004
	-----	-----
Cash provided by continuing operations.....	\$ 22,612	\$ 10,466
Cash used for investing activities.....	\$ (8,065)	\$ (3,080)
Cash used for financing activities.....	\$ (10,803)	\$ (22,447)

Unrestricted cash and cash equivalents include all highly liquid investments with an initial maturity of no more than three months at the date of purchase.

Restricted cash of approximately \$44,000 and \$51,000 at June 30, 2005, and December 31, 2004, respectively, represent amounts collected on behalf of certain Physician Services and Hospital Services clients, a portion of which is held in trust until it is remitted to such clients.

19

During the six months ended June 30, 2005, the Company generated approximately \$22.6 million in cash from continuing operations as a result of increased profitability and the timing of payments on certain liabilities.

During the six months ended June 30, 2004, the Company generated approximately \$10.5 million in cash from continuing operations, which includes cash generated from normal operations offset by cash payments related to additional procedures necessary under SAS No. 99 totaling approximately \$6.0 million (refer to "Note 4 -- Additional Procedures" in the Company's Notes to Consolidated Financial Statements for more information), the payment of approximately \$5.4 million in expenses and legal settlements related to the matter with Lloyd's of London (refer to "Note 12 -- Legal Matters" in the Company's Notes to Consolidated Financial Statements in the Company's 2004 Form 10-K for more information) and interest payments of approximately \$3.5 million.

During the six months ended June 30, 2005, the Company used approximately \$8.1 million in cash for investing activities primarily for capital expenditures and investment in software development costs. During the latter part of 2004, the Company initiated a project to enhance substantially its physician claims clearinghouse functionality. The Company expects that the improved platform will provide efficiencies and competitive advantages for its Physician Services division. The Company expects to incur approximately \$3 million in capital expenditures and capitalized software development costs during 2005. During the six months ended June 30, 2005, the Company invested approximately \$1.3 million for capital expenditures and capitalized software development costs related to this project.

During the six months ended June 30, 2004, the Company used approximately \$3.1 million in cash for investing activities primarily for capital expenditures and investment in software development costs.

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

During the six months ended June 30, 2005, the Company used approximately \$10.8 million in cash for financing activities which included approximately \$15.4 million used for the repurchase of the Company's Common Stock which was partially offset by proceeds from the exercise of stock options of approximately \$4.6 million.

On March 9, 2005, the Company announced that the Board authorized the repurchase of up to 1 million shares of the Company's outstanding Common Stock. Under the share repurchase program, the Company was able to repurchase shares from time to time at management's discretion in the open market, by block purchase, in privately negotiated transactions or as otherwise allowed by securities laws and regulations. All shares repurchased were placed into treasury to be used for general corporate purposes. During the six months ended June 30, 2005, the Company repurchased one million shares of its outstanding Common Stock at a cost of approximately \$15.4 million.

During the six months ended June 30, 2004, the Company used approximately \$22.4 million in cash for financing activities. On June 30, 2004 the Company raised \$125 million from the sale of 3.25% Convertible Subordinated Debentures due 2024 (the "Debentures") and retired the \$118.8 million then outstanding under the Term Loan B concurrently with the completion of the Convertible Debenture offering. On June 30, 2004, the Company also completed an amendment to the Revolving Credit Facility to increase its capacity and lower the Company's borrowing rate. The Revolving Credit Facility's capacity was expanded from \$50 million to \$75 million and the facility's maturity was extended to three years. The Company incurred a prepayment penalty on the early retirement of the Term Loan B totaling \$2.4 million in addition to financing costs of \$3.3 million related to the Debentures offering and amendment to the Revolving Credit Facility. The Company also repurchased, for approximately \$25 million, an aggregate of approximately 2.0 million shares of the Company's outstanding common stock, at the market price of \$12.57 per share, in negotiated transactions concurrently with the Debentures offering. The cost of the refinancing and purchase of common stock is offset by proceeds from the exercise of stock options of approximately \$5.3 million.

For more information about the Company's long-term debt, refer to "Note 10 -- Long-Term Debt" in the Company's Notes to Consolidated Financial Statements.

The level of the Company's indebtedness could adversely impact the Company's ability to obtain additional financing. A substantial portion of the Company's cash flow from operations could be dedicated to the payment of principal and interest on its indebtedness.

20

The Company is subject to claims, litigation and official billing inquiries arising in the ordinary course of its business. These matters include pending lawsuits involving claims that are not required to be separately described in this report, including a claim for breach of contract arising from a prior acquisition. That claim has been submitted to binding arbitration, which commenced in the second quarter of 2005 and is expected to reconvene in the third quarter of 2005. The Company believes that it has meritorious defenses to the claims and other issues asserted in such matters; however, there can be no assurance that such matters or any future legal matters will not have an adverse effect on the Company. Amounts of awards or losses, if any, in pending legal matters have not been reflected in the financial statements unless probable and reasonably estimable.

FORWARD-LOOKING STATEMENTS

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

Certain statements included in the Notes to Consolidated Financial Statements, Management's Discussion and Analysis of Financial Condition and Results of Operations, and elsewhere in this report including but not limited to certain statements set forth under the captions "Note 2 -- Stock-Based Compensation Plans," "Note 9 -- Legal Matters," "Note 10 -- Long-Term Debt," "Note 11 -- Income Taxes," "Results of Operations" and "Liquidity and Capital Resources," are "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements include, but are not limited to, the Company's expectations with respect to meritorious defenses to the claims and other issues asserted in pending legal matters, the effect of industry and regulatory changes on the Company's customer base, the impact of revenue backlog on future revenue, adoption of accounting standard regarding expensing of stock options, payment of additional interest to convertible debenture holders, future appropriateness of deferred tax asset valuation allowance, overall profitability and the availability of capital. Although the Company believes that the statements it has made are based on reasonable assumptions, they are based on current information and beliefs and, accordingly, the Company can give no assurance that its expectations will be achieved. In addition, these statements are subject to factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These factors include, but are not limited to, factors identified below under the caption "Factors That May Affect Future Results of Operations, Financial Condition or Business" and "Quantitative and Qualitative Disclosures about Market Risk." The Company disclaims any responsibility to update any forward-looking statements.

FACTORS THAT MAY AFFECT FUTURE RESULTS OF OPERATIONS, FINANCIAL CONDITION OR BUSINESS

Per-Se provides the following risk factor disclosures in connection with its continuing efforts to qualify its written and oral forward-looking statements for the safe harbor protection of the Reform Act and any other similar safe harbor provisions. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to, the following:

THE COMPANY HAS A SIGNIFICANT AMOUNT OF LONG-TERM DEBT AND OBLIGATIONS TO MAKE PAYMENTS, WHICH COULD LIMIT THE COMPANY'S FUNDS AVAILABLE FOR OTHER ACTIVITIES.

The Company has approximately \$125 million of long-term indebtedness and \$0.6 million in capital lease obligations and, as a result, is required to make interest and principal payments. If unable to make the required debt payments, the Company could be required to reduce or delay capital expenditures, sell certain assets, restructure or refinance the Company's indebtedness, or seek additional equity capital. The Company's ability to make payments on the Company's debt obligations will depend on future operating performance, which may be affected by conditions beyond the Company's control.

THE COMPANY IS REGULARLY INVOLVED IN LITIGATION, WHICH MAY EXPOSE THE COMPANY TO SIGNIFICANT LIABILITIES.

The Company is involved in litigation arising in the ordinary course of its business, which may expose it to loss contingencies. These matters include, but are not limited to, claims brought by former customers with respect to the operation of the Company's business. The Company has also received written demands from customers and former customers that have not yet resulted in legal action.

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

The Company may not be able to successfully resolve such legal matters, or other legal matters that may arise in the future. In the event of an adverse outcome with respect to such legal matters or other legal matters in which the Company may become involved, the Company's insurance coverage may not fully cover any damages assessed against the Company. Although the Company maintains all insurance coverage in amounts that it believes is sufficient for its business, such coverage may prove to be inadequate or may become unavailable on acceptable terms, if at all. A successful claim brought against the Company, which is uninsured or under-insured, could materially harm the Company's business, results of operations or financial condition.

THE PHYSICIAN MANAGEMENT OUTSOURCING BUSINESS IS HIGHLY COMPETITIVE AND THE COMPANY'S INABILITY TO SUCCESSFULLY COMPETE FOR BUSINESS COULD ADVERSELY AFFECT THE COMPANY.

The physician business management outsourcing business, especially for revenue cycle management, is highly competitive. The Company competes with regional and local physician reimbursement organizations as well as physician groups that provide their own business management services in house. Successful competition within this industry is dependent on numerous industry and market conditions. Potential industry and market changes that could adversely affect the Company's ability to compete for business management outsourcing services include an increase in the number of local, regional or national competitors providing comparable services and new alliances between healthcare providers and third-party payers in which healthcare providers are employed by such third-party payers.

THE BUSINESS OF PROVIDING SERVICES AND SOLUTIONS TO HOSPITALS FOR BOTH REVENUE CYCLE AND RESOURCE MANAGEMENT IS ALSO HIGHLY COMPETITIVE AND THE COMPANY'S INABILITY TO SUCCESSFULLY COMPETE FOR BUSINESS COULD ADVERSELY AFFECT THE COMPANY.

The business of providing services and solutions to hospitals for both revenue cycle and resource management is also highly competitive. The Company competes with traditional electronic data interface companies, outsourcing companies and specialized software vendors with national, regional and local bases. Some competitors have longer operating histories and greater financial, technical and marketing resources than the Company. The Company's successful competition within this industry is dependent on numerous industry and market conditions.

THE MARKETS FOR THE COMPANY'S SERVICES AND SOLUTIONS ARE CHARACTERIZED BY RAPIDLY CHANGING TECHNOLOGY, EVOLVING INDUSTRY STANDARDS AND FREQUENT NEW PRODUCT INTRODUCTIONS AND THE COMPANY'S INABILITY TO KEEP PACE COULD ADVERSELY AFFECT THE COMPANY.

The markets for the Company's services and solutions are characterized by rapidly changing technology, evolving industry standards and frequent new product introductions. The Company's ability to keep pace with changes in the healthcare industry may be dependent on a variety of factors, including the Company's ability to enhance existing products and services; introduce new products and services quickly and cost effectively; achieve market acceptance for new products and services; and respond to emerging industry standards and other technological changes.

Competitors may develop competitive products that could adversely affect the Company's operating results. It is possible that the Company will be unsuccessful in refining, enhancing and developing the Company's technology going forward. The costs associated with refining, enhancing and developing these systems may increase significantly in the future. Existing software and technology may become obsolete as a result of ongoing technological developments

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

in the marketplace.

THE HEALTHCARE MARKETPLACE IS CHARACTERIZED BY CONSOLIDATION, WHICH MAY RESULT IN FEWER POTENTIAL CUSTOMERS FOR THE COMPANY'S SERVICES.

In general, consolidation initiatives in the healthcare marketplace may result in fewer potential customers for the Company's services. Some of these types of initiatives include employer initiatives such as creating purchasing cooperatives (GPOs); provider initiatives, such as risk-sharing among healthcare providers and managed care companies through capitated contracts; and integration among hospitals and physicians into

22

comprehensive delivery systems. Consolidation of management and billing services through integrated delivery systems may result in a decrease in demand for the Company's business management outsourcing services for particular physician practices.

THE HEALTHCARE INDUSTRY IS HIGHLY REGULATED, WHICH MAY INCREASE THE COMPANY'S COSTS OF OPERATION.

The healthcare industry is highly regulated and is subject to changing political, economic and regulatory influences. Federal and state legislatures have periodically considered programs to reform or amend the U.S. healthcare system at both the federal and state level and to change healthcare financing and reimbursement systems, such as the Balanced Budget Act of 1997 and the Medicare Modernization Act of 2003. These programs may contain proposals to increase governmental involvement in healthcare, lower reimbursement rates or otherwise change the environment in which healthcare industry participants operate. Current or future government regulations or healthcare reform measures may affect the Company's business. Healthcare industry participants may respond by reducing their investments or postponing investment decisions, including investments in the Company's products and services.

Medical billing and collection activities are governed by numerous federal and state civil and criminal laws. Federal and state regulators use these laws to investigate healthcare providers and companies that provide billing and collection services. In connection with these laws, the Company may be subjected to federal or state government investigations and possible penalties may be imposed upon the Company, false claims actions may have to be defended, private payers may file claims against the Company, and the Company may be excluded from Medicare, Medicaid or other government-funded healthcare programs.

In the past, the Company has been the subject of federal investigations, and the Company may become the subject of false claims litigation or additional investigations relating to its billing and collection activities. Any such proceeding or investigation could have a material adverse effect on the Company's business.

Under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), final rules have been published regarding standards for electronic transactions as well as standards for privacy and security of individually identifiable health information. The HIPAA rules set new or higher standards for the healthcare industry in handling healthcare transactions and information, with penalties for noncompliance. The Company has incurred and will continue to incur costs to comply with these rules. Although management believes that future compliance costs will not have a material impact on the Company's results of operations, compliance with these rules may prove to be more costly than anticipated. Failure to comply with such rules may have a material adverse effect on the Company's business and may subject the Company to civil and

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

criminal penalties as well as loss of customers.

The Company relies upon third parties to provide data elements to process electronic medical claims in a HIPAA-compliant format. While the Company believes it will be fully and properly prepared to process electronic medical claims in a HIPAA-compliant format, there can be no assurance that third parties, including healthcare providers and payers, will likewise be prepared to supply all the data elements required to process electronic medical claims and make electronic remittance under HIPAA's standards. If payers reject electronic medical claims and such claims are processed manually rather than electronically, there could be a material adverse affect on the Company's business. The Company has made and expects to continue to make investments in product enhancements to support customer operations that are regulated by HIPAA. Responding to HIPAA's impact may require the Company to make investments in new products or charge higher prices.

Numerous federal and state civil and criminal laws govern the collection, use, storage and disclosure of health information for the purpose of safeguarding the privacy and security of such information. Federal or state governments may impose penalties for noncompliance, both criminal and civil. Persons who believe their health information has been misused or disclosed improperly may bring claims and payers who believe instances of noncompliance with privacy and security standards have occurred may bring administrative sanctions or remedial actions against offending parties.

Passage of HIPAA is part of a wider healthcare reform initiative. The Company expects that the debate on healthcare reform will continue. The Company also expects that the federal government as well as state

23

governments will pass laws and issue regulations addressing healthcare issues and reimbursement of healthcare providers. The Company cannot predict whether the government will enact new legislation and regulations, and, if enacted, whether such new developments will affect the Company's business.

THE TRADING PRICE OF THE COMPANY'S COMMON STOCK MAY BE VOLATILE AND NEGATIVELY AFFECT YOUR INVESTMENT.

The trading price of the Company's Common Stock may be volatile. The market for the Company's Common Stock may experience significant price and volume fluctuations in response to a number of factors including actual or anticipated quarterly variations in operating results, changes in expectations of future financial performance or changes in estimates of securities analysts, government regulatory action, healthcare reform measures, client relationship developments and other factors, many of which are beyond the Company's control. Furthermore, the stock market in general and the market for software, healthcare business services and high technology companies in particular, has experienced volatility that often has been unrelated to the operating performance of particular companies. These broad market and industry fluctuations may adversely affect the trading price of the Company's Common Stock, regardless of actual operating performance.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

INTEREST RATE SENSITIVITY

The Company invests excess cash in commercial paper, money market funds and other highly liquid short-term investments. Due to the limited amounts of these investments and their short-term nature, any fluctuation in the prevailing interest rates is not expected to have a material effect on the Company's

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

financial statements.

The Company has the option of entering into loans based on LIBOR or base rates under the Revolving Credit Facility. As such, if the Company were to borrow amounts under the Revolving Credit Facility, the Company could experience fluctuations in interest rates under the Revolving Credit Facility. The Company has not incurred any borrowings under the Revolving Credit Facility since inception.

The Company has a process in place to monitor fluctuations in interest rates and could hedge against significant forecast changes in interest rates, if necessary.

EXCHANGE RATE SENSITIVITY

The majority of the Company's revenue and expenses are denominated in U.S. dollars. As a result, the Company has not experienced any significant foreign exchange gains or losses to date. The Company conducts only limited business denominated in foreign currencies and does not expect material foreign exchange gains or losses in the future. The Company does not engage in any foreign exchange hedging activities.

ITEM 4. CONTROLS AND PROCEDURES

In connection with the evaluation of the Company's disclosure controls and procedures required by Rule 13a-15(b) under the Securities Exchange Act of 1934 (the "Exchange Act"), the Company's chief executive officer and chief financial officer concluded that, as of June 30, 2005, the Company's disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is (a) recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and (b) accumulated and communicated to the Company's management, including its chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. It should be noted, however, that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues within the Company have been detected. Furthermore, the design of any control system is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how unlikely. Because of these inherent limitations in a cost-effective control system, misstatements or omissions due to error or fraud may occur and not be detected.

24

In connection with the evaluation required by Rule 13a-15(d) under the Exchange Act, no changes in the Company's internal control over financial reporting that occurred during the quarter ended June 30, 2005, and that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting were identified.

25

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

The information required by this Item is included in "Note 9 -- Legal Matters" of Notes to Consolidated Financial Statements in Item 1 of Part I.

ITEM 2C. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

PERIOD	(A) TOTAL NUMBER OF SHARES PURCHASED	(B) AVERAGE PRICE PAID PER SHARE	(C) TOTAL NUMBER OF SHARES PURCHASED AS PART OF PUBLICLY ANNOUNCED PLANS	(D) MAXIMUM NUMBER OF SHARES THAT MAY YET BE PURCHASED UNDER THE PLAN
-----	-----	-----	-----	-----
April 1, 2005 through April 7, 2005.....	190,069	\$15.40	1,000,000	--

The plan to repurchase the Common Stock of the Company was announced on March 9, 2005. The Board of Directors of the Company authorized the repurchase of up to one million shares of the Company's Common Stock. The Company purchased 809,931 of such shares in March 2005, and completed the share repurchase program in April 2005.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The Company held its Annual Meeting of Stockholders on May 18, 2005. The following directors were elected at such meeting:

NOMINEE	BOARD TERM	VOTES FOR	VOTES WITHHELD
-----	-----	-----	-----
John W. Clay, Jr.	One Year	27,980,087	926,765
John W. Danaher, M.D.	One Year	28,036,381	870,471
Craig Macnab.....	One Year	28,747,222	159,630
David E. McDowell.....	One Year	28,794,320	112,532
Philip M. Pead.....	One Year	28,734,374	172,478
C. Christopher Trower.....	One Year	27,904,535	1,002,317
Jeffrey W. Ubben.....	One Year	28,026,099	880,753

A proposal to ratify the appointment of the firm of Ernst & Young LLP as independent auditors of the Company for 2005 also was voted upon at the Annual Meeting of Stockholders and was approved by the stockholders. Votes cast were 28,883,630 for; 16,053 against; and 7,169 abstained.

26

ITEM 6. EXHIBITS

(A) Exhibits

EXHIBIT
NUMBER

DOCUMENT

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

-----		-----
2.1	--	Asset Purchase Agreement dated as of June 18, 2003, among Misys Hospital Systems, Inc., Misys Healthcare Systems (International) Limited, Misys plc, Registrant, and PST Products, LLC., together with the First Amendment thereto dated as of June 28, 2003 (incorporated by reference to Exhibit 2.1 to Current Report on Form 8-K filed on August 5, 2003).
3.1	--	Restated Certificate of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the year ended December 31, 1999).
3.2	--	Restated By-laws of Registrant, as amended (incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed on July 29, 2005).
4.1	--	Rights Agreement dated as of February 11, 1999, between Registrant and American Stock Transfer & Trust Company (including form of rights certificates) (incorporated by reference to Exhibit 4 to Current Report on Form 8-K filed on February 12, 1999).
4.2	--	First Amendment to Rights Agreement dated as of February 11, 1999, between Registrant and American Stock Transfer & Trust Company, entered into as of May 4, 2000 (incorporated by reference to Exhibit 4.4 to Quarterly Report of Form 10-Q for the quarter ended March 31, 2000).
4.3	--	Second Amendment to Rights Agreement dated as of February 11, 1999, between Registrant and American Stock Transfer & Trust Company, entered into as of December 6, 2001, to be effective as of March 6, 2002 (incorporated by reference to Exhibit 4.12 to Annual Report on Form 10-K for the year ended December 31, 2001).
4.4	--	Third Amendment to Rights Agreement dated as of February 11, 1999, between Registrant and American Stock Transfer & Trust Company, entered into as of March 10, 2003 (incorporated by reference to Exhibit 4.13 to Annual Report on Form 10-K for the year ended December 31, 2002).
4.5	--	Fourth Amendment to Rights Agreement dated as of February 11, 1999, between Registrant and American Stock Transfer & Trust Company, entered into as of February 18, 2005 (incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed on February 22, 2005).
4.6	--	Indenture dated as of June 30, 2004, between Registrant and U.S. Bank National Association, as Trustee, relating to Registrant's 3.25% Convertible Subordinated Debentures Due 2024 (incorporated by reference to Exhibit 4.5 to Quarterly Report on Form 10-Q for the quarter ended June 30, 2004).
4.7	--	Resale Registration Rights Agreement dated as of June 30, 2004, between Registrant and Banc of America Securities LLC, as representative of the several initial purchasers of Registrant's 3.25% Convertible Subordinated Debentures Due 2024 (incorporated by reference to Exhibit 4.6 to Quarterly Report on Form 10-Q for the quarter ended June 30, 2004).
10.1	--	Per-Se Technologies, Inc. 2005 Senior Executive Incentive Compensation Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on May 23, 2005).
10.2	--	Per-Se Technologies, Inc. 2005 Senior Management Incentive Compensation Plan (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed on May 23, 2005).
10.3	--	Per-Se Technologies, Inc. Employees' Retirement Savings Plan (incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed on May 23, 2005).
31.1	--	Certification of Chief Executive Officer pursuant to

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

- Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 -- Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 -- Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 -- Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

27

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this amendment to be signed on its behalf by the undersigned thereunto duly authorized.

PER-SE TECHNOLOGIES, INC.
(Registrant)

By: /s/ CHRIS E. PERKINS

Chris E. Perkins
Executive Vice President and
Chief Financial Officer

By: /s/ RICHARD A. FLYNT

Richard A. Flynt
Vice President and Corporate
Controller
(Principal Accounting Officer)

Date: August 5, 2005

28

INDEX TO EXHIBITS

EXHIBIT NUMBER -----	DOCUMENT -----
2.1 --	Asset Purchase Agreement dated as of June 18, 2003, among Misys Hospital Systems, Inc., Misys Healthcare Systems (International) Limited, Misys plc, Registrant, and PST Products, LLC., together with the First Amendment thereto dated as of June 28, 2003 (incorporated by reference to Exhibit 2.1 to Current Report on Form 8-K filed on August 5, 2003).
3.1 --	Restated Certificate of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the year ended December 31, 1999).
3.2 --	Restated By-laws of Registrant, as amended (incorporated by

Edgar Filing: PER SE TECHNOLOGIES INC - Form 10-Q

- reference to Exhibit 3.2 to Current Report on Form 8-K filed on July 29, 2005).
- 4.1 -- Rights Agreement dated as of February 11, 1999, between Registrant and American Stock Transfer & Trust Company (including form of rights certificates) (incorporated by reference to Exhibit 4 to Current Report on Form 8-K filed on February 12, 1999).
 - 4.2 -- First Amendment to Rights Agreement dated as of February 11, 1999, between Registrant and American Stock Transfer & Trust Company, entered into as of May 4, 2000 (incorporated by reference to Exhibit 4.4 to Quarterly Report of Form 10-Q for the quarter ended March 31, 2000).
 - 4.3 -- Second Amendment to Rights Agreement dated as of February 11, 1999, between Registrant and American Stock Transfer & Trust Company, entered into as of December 6, 2001, to be effective as of March 6, 2002 (incorporated by reference to Exhibit 4.12 to Annual Report on Form 10-K for the year ended December 31, 2001).
 - 4.4 -- Third Amendment to Rights Agreement dated as of February 11, 1999, between Registrant and American Stock Transfer & Trust Company, entered into as of March 10, 2003 (incorporated by reference to Exhibit 4.13 to Annual Report on Form 10-K for the year ended December 31, 2002).
 - 4.5 -- Fourth Amendment to Rights Agreement dated as of February 11, 1999, between Registrant and American Stock Transfer & Trust Company, entered into as of February 18, 2005 (incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed on February 22, 2005).
 - 4.6 -- Indenture dated as of June 30, 2004, between Registrant and U.S. Bank National Association, as Trustee, relating to Registrant's 3.25% Convertible Subordinated Debentures Due 2024 (incorporated by reference to Exhibit 4.5 to Quarterly Report on Form 10-Q for the quarter ended June 30, 2004).
 - 4.7 -- Resale Registration Rights Agreement dated as of June 30, 2004, between Registrant and Banc of America Securities LLC, as representative of the several initial purchasers of Registrant's 3.25% Convertible Subordinated Debentures Due 2024 (incorporated by reference to Exhibit 4.6 to Quarterly Report on Form 10-Q for the quarter ended June 30, 2004).
 - 10.1 -- Per-Se Technologies, Inc. 2005 Senior Executive Incentive Compensation Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on May 23, 2005).
 - 10.2 -- Per-Se Technologies, Inc. 2005 Senior Management Incentive Compensation Plan (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed on May 23, 2005).
 - 10.3 -- Per-Se Technologies, Inc. Employees' Retirement Savings Plan (incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed on May 23, 2005).
 - 31.1 -- Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 - 31.2 -- Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 - 32.1 -- Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 - 32.2 -- Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.